Pipeline news

• Clearside Biomedical Appoints Thomas A. Ciulla, M.D., MBA as Chief Medical Officer

  25 October 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of  Thomas A. Ciulla , M.D., M.B.A. to the position of Chief Medical Officer.

• Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer

  25 October 2018

  

  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced it will provide an update on E2112, its NCI-sponsored, ECOG-ACRIN led pivotal trial of entinostat plus exemestane in hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) breast cancer as well as its registration strategy for entinostat in combination with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC).

• Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference

  22 October 2018

  

  Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today announced that results from the EMPIRE-CF Phase 2 study evaluating its investigational oral, once daily product, acebilustat, for the treatment of cystic fibrosis (CF) in 200 patients were presented at the North American Cystic Fibrosis Conference (NACFC) held October 18-20, 2018 in Denver, Colorado.  

• Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain

  19 October 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of  Thomas Crawford , CSCP, as Vice President, Supply Chain.

• Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance

  10 October 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice President of Clinical Development and Pharmacovigilance where he will primarily be responsible for the medical leadership of our postpartum depression (PPD) programs and drug safety.

• Atlas Genetics Announces Company Rebranding, Changes Name to Binx Health

  08 October 2018

  

  Atlas Genetics, a pioneer in near-patient testing solutions, has been renamed Binx Health, and has aligned with additional healthcare pioneers as it redefines new categories of convenient testing where people live, work and shop.

• Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®

  03 October 2018

  

  Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, today announced a worldwide licensing agreement with OcuNexus Therapeutics for NEXAGON®, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care.

• Clearside Biomedical Appoints Jeffrey Edwards to Board of Directors

  26 September 2018

  

  Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced that  Jeffrey Edwards  has been appointed to its Board of Directors, effective immediately.

• Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

  25 September 2018

  

  Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study – a Phase 2 clinical trial evaluating the safety, pharmacokinetics and efficacy of ganaxolone in women with postpartum depression.

• Syndax Announces Changes to its Board of Directors

  25 September 2018

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of  Jennifer Jarrett  and  William Meury to its Board of Directors, effective today.  Ms. Jarrett and Mr. Meury will succeed  Luke Evnin , Ph.D. and  Henry Chen , who resigned as active members of the Syndax Board of Directors, effective today.